Rosamond Deegan is the founder of OMass Therapeutics. OMass Therapeutics has raised $190M in total funding. Latest round: Series A. Based in Oxford, UK.
Rosamond Deegan is the Chief Executive Officer of OMass Therapeutics, an Oxford University spin-out founded in 2016. She was appointed CEO in May 2019 and led the company's strategic transition from services to therapeutics, expanding the team and overseeing a significant Series A fundraise.
Full founder directory · Investor directory · Company funding database · Fundraising library